Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that is characterised by raised blood glucose levels due to resistance to the action of insulin.
Introduction
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that is characterised by raised blood glucose levels due to resistance to the action of insulin.
T2DM represents a large clinical burden; approximately 2.9 million people were diagnosed with T2DM in 2013 in the UK, 1 and treating T2DM and its complications is estimated to cost £12 billion annually.
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A step-wise approach to treatment is typically used alongside lifestyle changes, to help patients achieve target glycated haemoglobin (HbA1c) levels. First-line therapy is usually metformin (met), followed by adding on a sulphonylurea (SU) for second-line. Current third-line options to create a triple therapy regimen consist of either adding oral agents (dipeptidyl peptidase-4 inhibitors [DPP4i] or thiazolidinedione), or injectables (insulin or glucagon-like peptide-1 [GLP-1] analogues).
Dapagliflozin belongs to the sodium-glucose co-transporter-2 (SGLT-2) inhibitor class, and acts by reducing glucose reabsorption from the proximal tubule of the kidney. Dapagliflozin was the first therapy in this novel class of insulin-independent, glucose-lowering medications.
Dapagliflozin at 10 mg once daily is licensed for the treatment of adults aged 18 years and older with T2DM to improve glycaemic control when used in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Dapagliflozin was accepted by the Scottish Medicines Consortium (SMC) for use in triple therapy in combination with met+SU, as an alternative to a DPP4i, on the basis of the costeffectiveness analysis presented below.
Objectives
To assess the cost-effectiveness of dapagliflozin compared to the DPP4i class, when used as triple oral therapy in combination with met+SU for the treatment of patients with T2DM who are inadequately controlled on met+SU alone.
Methods

Model structure
The validated CARDIFF diabetes model was used, which is a cost-utility model using discrete event simulation.
3
The model structure is shown in Figure 1 .
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as triple therapy in combination with metformin and a sulphonylurea in the treatment of type 2 diabetes mellitus from a UK healthcare perspective The 95% CrI's (from the NMA) were used as upper and lower limits for sensitivity analysis of the treatment effect parameters for dapagliflozin and the comparator. † Applied in sensitivity analysis only; the NMA did not find a significant difference in the odds ratio of hypoglycaemia so the probability of hypoglycaemic events was assumed to be the same for dapagliflozin and DPP4i's in the base case.
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The decrement applies for the first year of the event and all subsequent years, and is subtracted from age adjusted no complications utility. **For each 1 unit increase in BMI a utility decrement of -0.0061 is applied in the economic model, and for a unit decrease in BMI a utility increase of 0.0061 is applied. The model simulates a cohort of 30,000 patients over a 40-year time horizon, with a cycle length of 6 months.
Patients are treated with dapagliflozin or pooled DPP4i's as triple therapy in the first-line, with the only subsequent line of therapy being intensified insulin.
Within the model, patients experience natural progression (an increase) in HbA1c, weight and systolic blood pressure (SBP) over time.
-Introduction of a new treatment results in a treatment effect based on the inputs described below (Table 1 ).
-Weight changes are associated with a health-related quality of life (HRQoL) impact whilst on treatment and with cardiovascular risk over time.
-Incorporation of a treatment effect on HbA1c and SBP was included in the scenario analysis.
-Treatment switch to second-line treatment occurs when patients reach a defined HbA1c threshold -set at ≥8% in the base case.
The model considers hypoglycaemic episodes associated with therapeutic interventions and incorporates those adverse events (urinary tract infections [UTI] and genital infections [GI] ) that may be higher for an SGLT-2 therapy than for the DPP4i class.
Model inputs
Clinical effectiveness estimates for the cost-effectiveness analysis were established by a systematic review and network meta-analysis (NMA) of dapagliflozin and comparator DPP4i interventions as triple therapy with met+SU, which represented an update to the systematic review and NMA previously conducted and published by the Canadian Agency for Drugs and Technologies in Health (CADTH).
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DPP4i's were treated as a pooled class to increase the amount of data available for the NMA (Table 1 ).
-In the base case, only statistically significant treatment effects were applied; therefore treatment only impacted upon weight progression.
Utilities applied within the model are based on published utility data. Key disutilities applied are described in Table 1 .
Cost and resource use estimates were based on a Scottish healthcare perspective, though inputs are considered to be comparable to those that would apply in the UK setting.
The economic model considered costs and resource use associated with drug acquisition, T2DM complications, hypoglycaemia and UTI/GI adverse events. A summary of cost inputs to the economic model is provided in Table 2 . In addition, monitoring costs of £43 for a renal monitoring visit and £2.67 for a 24 hour creatinine clearance test were applied upon dapagliflozin initiation.
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Costs and quality-adjusted life years (QALYs) were discounted at 3.5% in the base case of the economic model.
Sensitivity analyses
Scenario, univariate and probabilistic sensitivity analyses were performed to assess the impact of assumptions and uncertainty in the model.
Results
Base case
The base case incremental cost-effectiveness ratio (ICER) for dapagliflozin as an add-on to met+SU compared to the DPP4i class in triple therapy was £10,995 per QALY gained (Table 3) . Prices of packs for calculation of price per tablet were sourced from the British National £-£20,000 £40,000 £60,000 £80,000 £100,000
Probability that the dapagliflozin treatment arm is cost-effective against the DPP4i treatment arm at different willingness-to-pay thresholds
Sensitivity analyses
Results of scenario analyses and univariate sensitivity analyses are presented in Table 3 . The most sensitive variable in univariate sensitivity analysis was associated with altering the weight change parameter according to the 95% credible intervals from the NMA.
Probabilistic sensitivity analysis (Figure 2 ) demonstrated that at a willingness-to-pay threshold of £20,000 per QALY, the probability that dapagliflozin is cost-effective compared to the DPP4i class in triple therapy is 58.9% (Figure 3) .
CHF: Congestive heart failure; CV: Cardiovascular; IHD: Ischaemic heart disease; MI: Myocardial infarction; QALY: Quality-adjusted life year 
Discussion
The incremental costs associated with dapagliflozin are primarily due to the additional drug acquisition cost.
The key driver of the cost-effectiveness results is the relative QALY gain versus the DPP4i's; the gain is associated with the superior weight control of dapagliflozin and the consequent HRQoL benefits associated with this, combined with similar HbA1c control and hence reduction in the risk of long-term cardiovascular complications.
The observed ICERs relate to very small differences in costs and QALYs over the time horizon considered.
The results are based on model inputs considered to be generalisable to Scotland, and are likely relevant to the UK more widely.
Conclusions
For patients whose T2DM is not well controlled with met+SU alone, dapagliflozin in combination with met+SU was shown to be cost-effective compared to the DPP4i class with a base case ICER of under £11,000 per QALY gained.
These analyses contributed to positive advice issued by the SMC for the use of dapagliflozin in adults aged 18 years and older with T2DM to improve glycaemic control as triple therapy in combination with met+SU, as an alternative to a DPP4i, when these, together with diet and exercise, do not provide adequate glycaemic control.
